Cannabis Use and its Medical Risks and Benefits: Leveraging Mobile Technology and Consumer Genomics

摘要 该R21项目实施了创新的在线/移动招聘和评估战略，并将其应用于 确定影响大麻使用的遗传因素以及相关的医疗风险和益处。太多时候，招聘 而且，为人类基因研究开发足够大的队列一直是缓慢而昂贵的。我们的 通过招募已经分型的消费者基因组学客户，该方法将大大减少时间和成本 并通过移动设备和互联网以电子方式评估其物质使用情况。建议的工作构建 关于我们获得2016年NIDA三等奖的成瘾基因组(GENA)移动应用原型 挑战：成瘾研究：有一款应用程序可以做到这一点。(https://www.drugabuse.gov/researchers/research- 资源/NIDA-挑战-计划)。具体地说，确定与大麻使用和相关医疗有关的基因 风险和收益，我们将：(1)最终确定并实施我们的“直接到参与者”接口，这将允许 参与者使用我们的移动应用程序和网站提供知情同意，回答大麻使用 问题，并确保他们现有的全基因组基因数据的安全访问；(2)招募和电子 为大麻使用特征的全基因组关联研究(GWAS)评估一个大的、有实力的队列 对公众健康很重要；(3)分析我们新的GWAS队列，以确定与医学相关的基因座 大麻的使用特征和数量使用频率。我们新颖的、直接面向参与者的协议将立即 解决高优先级物质--大麻，并建立一个应对新研究的平台 物质使用领域的需求。

ABSTRACT This R21 project implements an innovative online/mobile recruitment and assessment strategy and applies it to identify genetic factors that influence cannabis use and related medical risks and benefits. Too often, recruiting and developing sufficiently large cohorts for human genetic studies has been slow and expensive. Our approach will greatly reduce time and costs by recruiting already-genotyped consumer genomics customers and electronically assessing their substance use via mobile devices and the internet. The proposed work builds on our prototype Genomics of Addiction (GENA) mobile app that earned third prize in the 2016 NIDA Challenge “Addiction Research: There's an App for That” (https://www.drugabuse.gov/researchers/research- resources/nida-challenges-program). Specifically, to identify loci involved in cannabis use and related medical risks and benefits, we will: (1) Finalize and implement our “direct-to-participant” interface, which allows participants to use our mobile app and website to provide informed consent, answers to cannabis use questions, and secure access to their existing genome-wide genotype data; (2) Recruit and electronically assess a large, well-powered cohort for a genome-wide association study (GWAS) of cannabis use traits important to public health; (3) Analyze our new GWAS cohort to identify loci associated with medically relevant cannabis use traits and quantitative frequency of use. Our novel, direct-to-participant protocol will immediately address a high-priority substance, cannabis, and establish a platform for responding to emerging research needs in the substance use field.